Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study

INTRODUCTION: Although the direct oral anticoagulant rivaroxaban is recommended for stroke prevention in patients with non-valvular atrial fibrillation based on Phase III clinical trials, there is still a need for additional safety data from everyday clinical practice. The ROSE study was initiated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Alison, Davies, Miranda, Osborne, Vicki, Roy, Debabrata, Shakir, Saad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546486/
https://www.ncbi.nlm.nih.gov/pubmed/33035259
http://dx.doi.org/10.1371/journal.pone.0240489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546486/
https://www.ncbi.nlm.nih.gov/pubmed/33035259
http://dx.doi.org/10.1371/journal.pone.0240489

Ejemplares similares